Sekisui Kasei (4228) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although revenue declined, the Company achieved a substantial increase in profit during the quarter, making this an earnings release that requires careful assessment of underlying performance excluding temporary factors such as gains on asset sales. Revenue contracted to ¥2.561B (-19.9% YoY), while Operating Income expanded sharply to ¥0.104B (+298.1% YoY; operating margin of 4.1%) and Net Income to ¥0.180B (+472.3% YoY). The primary driver of profit growth was the improvement in the earnings structure, together with extraordinary income—including a ¥0.135B gain on the sale of fixed assets—which boosted Net Income. Accordingly, Operating Income and Ordinary Income should be given greater weight when evaluating recurring earnings power.

Factors Affecting Earnings

【Revenue】Revenue was ¥2.561B, down 19.9% YoY. The Industry segment contracted substantially to ¥1.128B (-40.8% YoY), with the sharp decline in sales in Europe—comprising the Czech Republic, Germany, and other European markets—being the primary cause of the Company-wide revenue decline. In contrast, the Human Life segment increased revenue to ¥1.433B (+10.9% YoY), supporting the overall earnings mix.

【Profit and Loss】Operating Income was ¥0.104B (+298.1% YoY), while the operating margin was 4.1%, improving from approximately 0.8% in the previous year. Ordinary Income was ¥0.116B (+426.8% YoY), with dividend income of ¥0.023B and foreign exchange gains of ¥0.005B partially offsetting interest expenses of ¥0.016B. Net Income was ¥0.180B (+472.3% YoY); however, pretax income of ¥0.235B included ¥0.135B in extraordinary income, primarily from gains on the sale of fixed assets, and extraordinary losses of ¥0.016B, including impairment losses of ¥0.002B. While profitability improved at the operating level, the increase in Net Income was significantly supported by temporary factors. In conclusion, the Company achieved higher profit despite lower revenue.

Segment Analysis

Segment profit was ¥0.102B in the Human Life segment (+80.6% YoY; margin of 7.1%) and ¥0.094B in the Industry segment (+155.0% YoY; margin of 8.3%), with margins improving in both segments. The Human Life segment became the largest source of profit through higher revenue and profit. Meanwhile, Industry segment profit increased substantially despite a 40.8% decline in revenue, apparently reflecting cost reductions and improved profitability. However, as this improvement occurred amid declining revenue, its sustainability requires further assessment. Against total segment profit of ¥0.197B, Company-wide expenses and other adjustments amounted to -¥0.080B (previous year: -¥0.072B), resulting in consolidated Ordinary Income of ¥0.116B.

Key Financial Indicators

【Profitability】The operating margin of 4.1% improved from approximately 0.8% in the same period of the previous year, but Revenue declined 19.9%, meaning that the sustainability of fixed-cost absorption will depend on future revenue trends. The Net Income margin expanded to 7.0% from approximately 1.0% in the previous year, partly reflecting the contribution from gains on the sale of fixed assets.【Cash Flow Quality】Operating Cash Flow (OCF) was limited to ¥0.023B, and its ratio to Net Income of ¥0.180B was low at 0.13x, primarily due to increases of ¥0.233B in trade receivables and ¥0.101B in inventories. The ¥0.299B increase in trade payables partially offset these outflows.【Investment Efficiency】ROE was 3.4%, indicating a limited level of capital efficiency under an Equity Ratio of 42.0%. Capital expenditures of ¥0.101B were below depreciation and amortization of ¥0.124B, suggesting an investment policy centered on replacement spending.【Financial Soundness】The Equity Ratio of 42.0% is stable; however, the composition of interest-bearing debt, including ¥2.400B in long-term borrowings and ¥0.700B in bonds due within one year, requires ongoing management of repayment and refinancing plans.

Cash Flow Analysis

Operating Cash Flow (OCF) was ¥0.023B, down 47.6% YoY, representing a substantial divergence from Net Income of ¥0.180B. The primary factors were working-capital cash outflows resulting from a ¥0.233B increase in trade receivables and a ¥0.101B increase in inventories, partially offset by a ¥0.300B increase in trade payables. Investing Cash Flow was positive at ¥0.062B, reflecting proceeds from the sale of property, plant and equipment exceeding capital expenditures of ¥0.101B. Financing Cash Flow was -¥0.111B, reflecting cash outflows primarily from repayments of long-term borrowings. Free Cash Flow was ¥0.085B, but this was substantially supported by proceeds from asset sales; therefore, improvement in OCF should be monitored when assessing recurring cash-generation capacity.

Earnings Quality

Net Income of ¥0.180B exceeded Ordinary Income of ¥0.116B, creating a significant divergence. The primary cause was the net amount of extraordinary income of ¥0.135B—mainly gains on the sale of fixed assets—and extraordinary losses of ¥0.016B, including impairment losses of ¥0.002B. These items did not arise from recurring business activities. Non-operating income of ¥0.034B represented 1.3% of Revenue and consisted primarily of dividend income of ¥0.023B; there was no excessive dependence on non-operating income. On the other hand, OCF was limited to ¥0.023B due to an increase in working capital, indicating weak cash conversion of Net Income and a substantial divergence between accrual-based earnings and cash flow. Based on the above, the sharp increase in Net Income for the current period was significantly driven by temporary factors, and Operating Income, Ordinary Income, and OCF should be the primary metrics for evaluating sustainable earnings power.

Earnings Forecast and Guidance

The full-year forecasts are Revenue of ¥10.500B (-7.8% YoY), Operating Income of ¥0.310B (+21.5% YoY), and Ordinary Income of ¥0.260B (+15.6% YoY). Progress against the full-year forecast in Q1 was 24.4% for Revenue, 33.7% for Operating Income, and 44.8% for Ordinary Income, exceeding the standard quarterly benchmark of 25%. However, the high progress rate for Ordinary Income does not include temporary extraordinary gains or losses, and includes a certain contribution from non-operating income; consequently, the pace of progress may normalize going forward. Net Income progress was high at 71.8%, but this was primarily due to the ¥0.135B gain on the sale of fixed assets and does not directly indicate upside potential for the full year. The Company revised its earnings forecast during the quarter, and recovery in Industry segment revenue and trends in the European business will be the key factors in achieving the full-year targets.

Shareholder Returns

The full-year dividend forecast is ¥17.00 per share, and no revision was made to the dividend forecast during the period. Using the period-average number of shares outstanding of 45,598 thousand shares, the annual dividend payment is estimated at approximately ¥0.78B, implying a Payout Ratio of approximately 31.0% against the full-year Net Income forecast of ¥2.50B. Free Cash Flow of ¥0.85B is at a level that generally covers the projected annual dividend amount; however, OCF was limited to ¥0.23B, making improvement in OCF a key issue for the cash-based funding source. No share repurchase was identified, and the assessment is based solely on the Payout Ratio.

Risk Factors

1. Revenue decline risk in the Industry segment and European business: Revenue in the Industry segment declined 40.8% YoY, with sales in the Czech Republic, Germany, and other European markets contracting substantially. A delay in the recovery of overseas demand could cause downside risk to Company-wide revenue.

2. Working-capital cash commitment risk: OCF was limited to ¥0.23B, with a low ratio of 0.13x relative to Net Income of ¥18.0B. The primary factors were increases of ¥23.3B in trade receivables and ¥10.1B in inventories, making inventory and receivables management a key issue during periods of demand fluctuations.

3. Balance between interest-bearing debt and earnings: The Company has interest-bearing debt, including ¥240.0B in long-term borrowings and ¥70.0B in bonds due within one year, while its Operating Income level during the quarter remained limited. The impact on debt-servicing burdens should continue to be closely monitored if the pace of earnings recovery is delayed.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The operating margin is below the industry median, while the Net Income margin is broadly in line with the industry, partly due to the contribution from extraordinary income.

Growth and Capital Efficiency

The Revenue growth rate is substantially below the industry median, and the Company’s revenue decline is notable even within the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings Release

1. Operating Income increased +298.1% YoY, and the operating margin also improved by approximately 3.3pt; however, Revenue declined 19.9%, meaning that the sustainability of profit growth will depend on whether top-line recovery materializes.

2. The substantial increase in Net Income was significantly supported by the ¥0.135B gain on the sale of fixed assets. Operating Income, Ordinary Income, and OCF should therefore be prioritized as indicators of recurring earnings power.

3. While the Human Life segment drove profit through higher revenue and profit, the Industry segment experienced lower revenue due to the sharp decline in European sales. Recovery trends by region and segment will therefore be key areas of focus in evaluating future performance.

Theoretical Share Price (Reference Value)

Sensitivity: ¥989–¥1,047 at ±1% for the cost of equity, and ¥1,013–¥1,021 at ±0.1 for ω.

Notes:

• Because Net Income progress against the full-year forecast (72%) exceeds the standard level (25%), forecast EPS has been adjusted upward within an upper limit of +10% (because companies progressing ahead of forecast tend to exceed their forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value Per Share.
• Net assets as of the quarter-end are used; there is a timing difference relative to the full-year forecast.
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional adviser as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 showed a sharp recovery in operating profitability despite a 19.9% YoY decline in revenue to ¥25.61bn. Operating income rose 298.1% YoY to ¥1.04bn, lifting the operating margin to 4.1% from 0.8% a year earlier, an expansion of approximately 326bp. Gross profit increased 2.8% YoY to ¥6.75bn even as sales declined, with the gross margin improving to 26.4% from 20.6%, or about 581bp. SG&A expense declined 9.5% YoY to ¥5.71bn, although the reduction was smaller than the sales decline and therefore did not provide operating leverage at the SG&A level. The earnings recovery was driven principally by gross-margin normalization and much stronger segment profitability. Ordinary income increased 426.8% YoY to ¥1.16bn, supported by ¥0.23bn of dividend income and ¥0.47bn of foreign-exchange gains. Net income attributable to owners increased 476.8% YoY to ¥1.80bn, but this result was materially supported by extraordinary items. Specifically, the company recorded a ¥1.35bn gain on sales of fixed assets, partly offset by ¥0.23bn of impairment loss, ¥0.13bn loss on business liquidation and other extraordinary losses, resulting in net extraordinary gains of approximately ¥1.19bn. Accordingly, the substantial improvement in reported net margin to 7.0% should not be regarded as fully recurring. The annualized ROE was 13.5%, within a good range, but was elevated by the Q1 extraordinary gain and 2.38x financial leverage. Cash conversion was weak: operating cash flow was only ¥0.23bn against ¥1.80bn of net income. The cash shortfall reflected a ¥2.33bn increase in trade receivables and a ¥1.01bn inventory increase, partially offset by a ¥3.00bn increase in trade payables. The reported free cash flow was positive ¥8.49bn because investing cash flow included ¥2.65bn of proceeds from fixed-asset sales; this does not represent recurring operating cash generation. Liquidity remains adequate, with a 132.7% current ratio and 113.9% quick ratio, while debt service capacity is supported by 14.1x EBITDA interest coverage. However, debt/EBITDA of 13.7x remains high and requires sustained improvement in normalized EBITDA and cash conversion. Against the full-year plan, Q1 revenue progress was 24.4%, broadly in line with the 25% seasonal reference point, while operating-income progress was 33.7% and ordinary-income progress was 44.8%, ahead of the standard pace. Net-income progress of 71.8% is substantially ahead of plan but largely reflects the fixed-asset disposal gain. The key implication is that the operating turnaround is credible at the gross-profit level, but the investment case depends on converting this improvement into recurring cash earnings while managing leverage and receivable intensity.

Profitability Analysis

The annualized DuPont ROE is 13.5%, decomposed into a 7.0% net profit margin, 0.811x asset turnover and 2.38x financial leverage. Financial leverage is a meaningful contributor to the reported return profile, while the net margin is inflated by the net ¥1.19bn extraordinary gain. The largest underlying operating change was margin recovery: gross margin rose approximately 581bp YoY to 26.4%, and operating margin rose approximately 326bp to 4.1%. This indicates that lower input costs, pricing/mix, production efficiency, or a combination of these factors more than offset the 19.9% revenue contraction. SG&A fell to ¥5.71bn from ¥6.31bn, but its 9.5% decline lagged the sales decline, implying modest negative operating leverage below gross profit. EBITDA rose to ¥2.28bn and the EBITDA margin reached 8.9%, providing a clearer view of operating earnings before depreciation and the extraordinary gain. The EBIT margin of 4.1% remains below the 5% efficiency threshold, so profitability has improved substantially but is not yet at a robust level for a diversified manufacturing company. The five-factor framework shows a 76.4% tax burden, which is normal, while the interest-burden ratio exceeds 1.0 because profit before tax was boosted by extraordinary gains rather than because financing costs are immaterial. Interest expense of ¥0.16bn was covered 6.44x by EBIT and 14.09x by EBITDA, indicating manageable near-term interest servicing. The annualized 4.3% ROIC remains below the 5% benchmark, suggesting that the recovery in operating profit has not yet translated into an adequate return on the capital base. Sustainability therefore depends on maintaining the gross-margin recovery, restoring sales volume in the Industry business, and reducing reliance on asset-sale gains.

Growth Assessment

Revenue declined 19.9% YoY to ¥25.61bn, with the contraction concentrated in the Industry segment. Human Life revenue increased 10.9% YoY to ¥14.33bn, while segment profit increased 80.6% to ¥10.24bn; its segment margin improved to 7.1% from 4.4%. Industry revenue declined 40.8% YoY to ¥11.28bn, but segment profit rose to ¥9.41bn from ¥3.69bn and segment margin expanded to 8.3% from 1.9%. Human Life was the core business by segment-profit contribution, although Industry delivered the stronger segment margin in Q1. Domestic sales increased to ¥20.72bn from ¥18.58bn, while Industry sales in Europe declined sharply, including Czech sales falling to ¥0.43bn from ¥32.13bn, German sales to ¥2.45bn from ¥29.92bn, and other European sales to ¥2.89bn from ¥32.83bn. The regional mix shift makes recovery in overseas industrial demand a central determinant of revenue normalization. The full-year forecast calls for revenue of ¥105.0bn, down 7.8% YoY, operating income of ¥3.10bn, up 21.5%, and ordinary income of ¥2.60bn, up 15.6%. Q1 revenue represents 24.4% of the full-year target, close to the 25% reference pace. Q1 operating income already represents 33.7% of the full-year forecast, suggesting a favorable start to the operating-profit target. However, Q1 ordinary income represents 44.8% of the annual target and net income represents 71.8% of forecast attributable profit, with the latter heavily influenced by the disposal gain. The forecast therefore appears achievable on the Q1 operating run rate, but the normalized earnings trajectory should be assessed using operating profit and EBITDA rather than reported net income.

Financial Health

Liquidity is adequate, with current assets of ¥56.20bn against current liabilities of ¥42.36bn, producing a 132.7% current ratio and ¥13.84bn of working capital. The 113.9% quick ratio indicates that short-term obligations are covered without reliance on inventory liquidation. Cash and deposits totaled ¥10.44bn, exceeding short-term loans of ¥7.35bn by 1.42x. Including the ¥7.00bn current portion of bonds payable, however, cash alone does not fully cover all disclosed near-term debt maturities, making continued access to operating cash flow and refinancing markets important. Interest-bearing loans were ¥31.35bn, comprising ¥7.35bn of short-term loans and ¥24.00bn of long-term loans; 23.5% of loan debt is short term. Debt-to-equity was 1.38x, below the 2.0x aggressive-leverage warning level, and debt/capital was 37.1%, within the 40% investment-grade reference level. Nevertheless, debt/EBITDA of 13.73x is materially above the 4.0x high-yield benchmark and is the principal balance-sheet risk. This ratio is especially important because EBITDA is calculated from a single quarter and cash conversion is currently weak. EBITDA interest coverage of 14.09x and EBIT interest coverage of 6.44x provide a meaningful near-term buffer against the current interest burden. Total equity increased to ¥53.08bn from ¥50.95bn, supported by ¥2.82bn of comprehensive income. Owners' equity accounted for ¥52.32bn, while non-controlling interests were limited at ¥0.76bn. Defined-benefit liabilities of ¥4.16bn are a continuing fixed obligation, but are modest relative to total equity. Intangible assets were only 1.2% of total assets, limiting balance-sheet dependence on intangible asset values.

Notable B/S Changes

Total assets: +¥40.07bn (+3.3%) to ¥1,263.62bn - balance-sheet expansion was concentrated in working-capital and valuation-related movements. Accounts receivable: +¥19.33bn (+9.9%) to ¥214.32bn - receivable growth despite lower revenue contributed to weak operating cash flow and the 76-day annualized DSO. Electronic receivables: +¥5.16bn (+5.9%) to ¥92.11bn - adds to the increase in customer-related receivable exposure and reinforces the collection-efficiency focus. Accounts payable: +¥20.73bn (+19.0%) to ¥129.92bn - supplier financing partly offset receivable and inventory cash absorption in Q1. Electronic payables: +¥8.55bn (+12.5%) to ¥77.12bn - increased use of electronic settlement obligations supported quarter-end working capital. Raw materials: +¥6.64bn (+17.2%) to ¥45.29bn - higher input inventory increases exposure to demand, input-price and inventory-management risk. Finished goods: +¥4.37bn (+5.8%) to ¥79.50bn - inventory increased while consolidated revenue declined, requiring monitoring for demand normalization and inventory turnover. Property, plant and equipment: -¥11.14bn (-2.3%) to ¥476.37bn - reduction was driven in part by fixed-asset sales that generated a ¥13.50bn extraordinary gain, supporting Q1 profit and investing cash flow but not recurring operations. Land: -¥8.92bn (-4.3%) to ¥198.05bn - land disposal was a major component of the fixed-asset sale activity and contributed to non-recurring earnings. Total equity: +¥21.33bn (+4.2%) to ¥530.78bn - Q1 comprehensive income of ¥28.18bn strengthened equity, including positive valuation differences on securities.

Cash Flow Quality

Cash-flow quality was weak in Q1. Operating cash flow was ¥0.23bn, equivalent to only 0.13x net income of ¥1.80bn and well below the 0.8x quality threshold. Cash conversion, measured as operating cash flow divided by EBITDA, was only 0.10x, confirming that the EBITDA recovery did not translate into cash generation during the quarter. The principal working-capital outflow was a ¥2.33bn increase in trade receivables, alongside a ¥1.01bn inventory increase. The receivable build is significant in the context of revenue decline and aligns with the 76-day annualized DSO quality alert, above the 60-day warning threshold. A ¥3.00bn increase in trade payables partly funded working capital, which mitigated the immediate cash impact but should be monitored for reversals in subsequent quarters. The reported accruals ratio was 1.2%, below the 5% benchmark, which is more favorable than the OCF/net-income metric; however, the latter is the more relevant Q1 signal because cash realization was low. Capital expenditure was ¥1.01bn, below depreciation and amortization of ¥1.24bn, resulting in a 0.82x CapEx/depreciation ratio. This is near maintenance level but below 1.0x, indicating that current investment is not yet consistent with a broad capacity-expansion cycle. Reported free cash flow was positive ¥8.49bn, supported by ¥6.16bn of investing cash inflow, including ¥2.65bn of proceeds from fixed-asset sales. On a conventional operating-cash-flow-less-capex basis, underlying pre-financing cash flow was negative approximately ¥0.78bn. Consequently, the positive reported free cash flow should not be interpreted as recurring cash coverage for capital allocation commitments. Financing cash outflow of ¥11.09bn included ¥26.89bn of long-term debt repayment, partly offset by ¥15.66bn of short-term borrowing and ¥7.00bn of new long-term loans, while cash dividends paid were ¥6.59bn.

Dividend Sustainability

The full-year dividend forecast is ¥17.00 per share, compared with forecast EPS of ¥54.83, implying a dividend payout ratio of approximately 31.0%. This is below the 60% sustainability benchmark and leaves a meaningful portion of forecast earnings available for debt reduction, working capital and investment. Using 45.60 million average shares, the indicated annual dividend cash requirement is approximately ¥0.78bn. Forecast attributable profit of ¥2.50bn would cover this dividend requirement by roughly 3.2x. However, Q1 operating cash flow of ¥0.23bn was below both the annualized dividend run rate and the ¥0.66bn of cash dividends paid in the quarter. Reported free cash flow was positive, but it was assisted by proceeds from fixed-asset sales and should not be treated as the core source of dividend funding. Dividend sustainability is therefore acceptable under the full-year earnings plan, but depends on receivable collection, normalization of working capital, and preservation of EBITDA rather than reliance on non-recurring gains. The absence of a disclosed share-repurchase amount means the analysis is confined to the dividend payout ratio rather than a total return ratio.

Risk Assessment

Business risks include Industry-segment revenue fell 40.8% YoY to ¥11.28bn, with a particularly sharp decline in European sales. A prolonged weakness in overseas industrial demand would limit volume recovery and could reverse part of the Q1 margin improvement., The manufacturing cost base remains exposed to raw-material, energy and logistics cost volatility. The Q1 gross-margin recovery is encouraging, but its durability depends on pricing discipline, procurement conditions and product mix., The chemical and functional-materials business faces product-quality, customer qualification, environmental regulation and production-disruption risks. These risks can generate abrupt costs, customer claims or volume losses., Foreign-exchange movements affect overseas operations and earnings translation. Q1 included ¥0.47bn of foreign-exchange gains, equal to about 45% of operating income, indicating that currency effects can materially influence below-the-line profitability..

Financial risks include Debt/EBITDA of 13.7x is high relative to the 4.0x high-yield benchmark. The root cause is a debt base of ¥31.35bn relative to Q1 EBITDA of ¥2.28bn; the impact is reduced financial flexibility if EBITDA weakens or refinancing costs rise., Operating cash flow of ¥0.23bn was only 13% of net income. The root cause was working-capital absorption, notably higher receivables and inventories; the impact is that accounting earnings currently provide limited internal funding for debt service, dividends and investment., Annualized DSO of 76 days exceeds the 60-day warning threshold. This suggests slower cash collection or a less favorable sales/payment mix, and increases the risk that revenue growth or quarter-end sales translate slowly into cash., Current debt maturities include ¥7.35bn of short-term loans and ¥7.00bn of current bonds payable. Although liquidity ratios are above 1.0x and cash exceeds short-term loans, maturity management remains important..

Key concerns include Reported net income was materially assisted by approximately ¥1.19bn of net extraordinary gains, primarily the ¥1.35bn gain on sales of fixed assets. This reduces comparability of the 7.0% net margin and 13.5% annualized ROE., The EBIT margin improved to 4.1% but remains below the 5% operating-efficiency threshold. Sustained profitability improvement requires further margin resilience rather than only cost recovery., The positive ¥8.49bn reported free cash flow was driven by investing inflows, including asset-sale proceeds, while conventional operating cash flow less capex was negative. This limits the quality of apparent cash generation., The annualized ROIC of 4.3% is below the 5% benchmark, indicating that the current earnings level has not yet fully covered the return requirement on the operating capital base..

Investment Implications

Key takeaways include Operating recovery is substantial: operating income rose to ¥1.04bn and operating margin expanded 326bp YoY to 4.1%, despite lower sales., Gross-margin expansion of approximately 581bp was the principal earnings driver, while SG&A reduction lagged revenue contraction., Human Life is the core profit contributor at ¥10.24bn of segment profit, while Industry delivered the highest Q1 segment margin at 8.3% despite a severe revenue decline., Q1 operating-profit progress of 33.7% versus the full-year forecast is ahead of the normal 25% pace, but net-profit progress is distorted by the fixed-asset disposal gain., Leverage and working-capital cash absorption remain the main constraints: debt/EBITDA is 13.7x, OCF/net income is 0.13x, and annualized DSO is 76 days., The ¥17 per-share dividend plan implies a moderate 31% forecast payout ratio, but sustainable funding requires stronger recurring operating cash flow..

Metrics to watch include Industry-segment revenue, particularly the pace of European industrial-sales recovery, Gross margin and operating margin, to determine whether Q1 margin recovery is sustainable, Operating cash flow, OCF/net income and OCF/EBITDA cash conversion, Trade receivables, annualized DSO and inventory movements, Debt/EBITDA, long-term debt repayment/refinancing and interest coverage, Recurring profit excluding gains or losses on fixed-asset disposals and impairments, Progress against the ¥105.0bn revenue and ¥3.10bn operating-income full-year forecasts.

Regarding relative positioning, The company combines an improving operating-margin profile and adequate short-term liquidity with below-target capital efficiency, high EBITDA-based leverage and weak Q1 cash conversion. Relative to manufacturing benchmarks, the 8.9% EBITDA margin and 13.5% annualized ROE are constructive, but the 4.1% EBIT margin, 4.3% annualized ROIC, 13.7x debt/EBITDA and 76-day annualized DSO indicate that normalized cash returns and balance-sheet efficiency remain the critical differentiators.